quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:08:39·1d
SECFiling
Veracyte Inc. logo

SEC Form DEFA14A filed by Veracyte Inc.

VCYT· Veracyte Inc.
Health Care
Original source

Companies

  • VCYT
    Veracyte Inc.
    Health Care

Recent analyst ratings

  • Apr 13UpdateJefferies$45.00
  • Dec 2UpdateMorgan Stanley$48.00
  • Oct 20UpdateCanaccord Genuity$40.00
  • Mar 20UpdateCraig Hallum$45.00
  • Dec 5UpdateGoldman$37.00
  • Nov 15UpdateWolfe Research$50.00

Related

  • SEC1d
    SEC Form DEF 14A filed by Veracyte Inc.
  • INSIDER9d
    SEC Form 4 filed by Haas Kevin Richard
  • PR9d
    Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026
  • ANALYST10d
    Jefferies initiated coverage on Veracyte with a new price target
  • SEC27d
    Amendment: SEC Form SCHEDULE 13G/A filed by Veracyte Inc.
  • INSIDER29d
    SEC Form 3 filed by new insider Haas Kevin Richard
  • SEC38d
    Veracyte Inc. filed SEC Form 8-K: Leadership Update
  • PR38d
    Veracyte Names Kevin Haas as Chief Development and Technology Officer
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022